Study on the Safety and Effectiveness of Livmoniplimab and Budigalimab for Liver Cancer

Inclusion Criteria

• Have a Child-Pugh A classification, which indicates good liver function.
• Have a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have previously received an immune checkpoint inhibitor as part of their first treatment for liver cancer.
• Have good blood and organ function.
• Be willing to have a tissue biopsy at the start of the study.
• Have liver cancer that cannot be treated with surgery or local therapies, or that has worsened after such treatments.

Exclusion Criteria

• Have untreated or worsening cancer that has spread to the brain or spinal cord.
• Have previously been treated with certain drugs like sorafenib or lenvatinib for liver cancer.
• Have had another type of cancer within the last 5 years, except for liver cancer.
• Have liver-related brain issues or need medication to manage these issues.
• Have moderate or severe fluid buildup in the abdomen that requires frequent treatment.
• Have active infections with both hepatitis B and C.
• Have had severe immune-related side effects from previous treatments.
• Have had repeated lung inflammation or pneumonia.